DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

Information source: Mayo Clinic
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Obesity

Intervention: Exenatide (Drug); placebo (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Mayo Clinic

Official(s) and/or principal investigator(s):
Michael Camilleri, MD, Principal Investigator, Affiliation: Mayo Clinic

Summary

The overall goal is to determine the effect of Exenatide on gastric emptying, satiety and satiation in obese participants.

Clinical Details

Official title: Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: The Effect of Exenatide on Gastric Emptying in Obese Participants

Secondary outcome: The effect of Exenatide on Gastric Emptying in Obese Participants

Detailed description: To evaluate the effect of Exenatide 5mcg SQ twice daily for 30-days on gastric emptying, satiety, satiation and weight loss in obese participants with TCF7L2 "CC compared to TT' genotype.

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Obese subjects with BMI> 30 Kg/m2: Otherwise healthy individuals who are not

currently on treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, endocrine (other than hyperglycemia not requiring medical therapy) and unstable psychiatric disease.

- Age: 18-70 years

- Gender: Men or women. Women of childbearing potential will have negative pregnancy

test before initiation of medication.

- Gastric emptying: Accelerated GE T1/2 < 79 minutes or GE 1h>35 %

Exclusion Criteria:

- Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes

Association criteria

- Unstable heart disease as evidenced by ongoing angina

- Congestive heart failure

- Concomitant use of appetite suppressants (i. e. caffeine based or diethylpropion) or

orlistat (Xenical®)

- Uncontrolled hypertension (Blood pressure greater than 160/90 mmHg)

- use of anti-diabetic drugs including metformin,

- history of nephrolithiasis,

- Recurrent major depression, presence or history of suicidal behaviour or ideation

with intent to act, and current substantial depressive symptoms (Patient Health Questionnaire [PHQ-9]21 total score ≥10).

- Gastroparesis

- Inflammatory bowel disease or irritable bowel syndrome

- Malignancy treated with chemotherapy within the past 3 years

- History of pancreatitis

- Renal insufficiency (eGFR less than 50 ml/min)

- Concomitant use of MAOI inhibitors (i. e. phenelzine, selegiline), serotonergic

agents, and other centrally acting appetite suppressants

- Significant psychiatric dysfunction based upon screening with the Hospital Anxiety

and Depression Scale [HADS] self-administered alcoholism screening test (SAAST, substance abuse) and the questionnaire on eating and weight patterns (binge eating disorders and bulimia). If such a dysfunction is identified by a HADS score ≥11 in any of the subscales or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.

- Intake of medication that could interfere with the interpretation of the study or

cause drug interaction (i. e. ketoconazole, erythromycin). Specifically, birth control pill, estrogen replacement therapy, and thyroxine replacement are permissible.

Locations and Contacts

Mayo Clinic, Rochester, Minnesota 55905, United States
Additional Information

Starting date: June 2014
Last updated: July 9, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017